Brief: Ars Pharmaceuticals Announces Scheduling Of A Type A Meeting With The U.S. FDA For Neffy® (Epinephrine Nasal Spray)

ARS Pharmaceuticals

06/10/2023 15:12

Oct 6 (Reuters) - ARS Pharmaceuticals Inc  SPRY.O :
    * ARS PHARMACEUTICALS ANNOUNCES SCHEDULING OF A TYPE A
MEETING
WITH THE U.S. FDA FOR NEFFY® (EPINEPHRINE NASAL SPRAY)
    * ARS PHARMACEUTICALS ANNOUNCES SCHEDULING OF A TYPE A
MEETING
WITH THE U.S. FDA FOR NEFFY® (EPINEPHRINE NASAL SPRAY)
    * ARS PHARMACEUTICALS INC - TYPE A MEETING WITH FDA WILL BE
HELD
BY END OF OCTOBER
    * ARS PHARMACEUTICALS-PLANS TO COMPLETE REPEAT DOSE STUDY
WITH
NEFFY IN ALLERGEN-INDUCED ALLERGIC RHINITIS, FILE ITS NDA
RESUBMISSION TO FDA IN H1 2024
    * ARS PHARMACEUTICALS INC - ANTICIPATED LAUNCH OF NEFFY, IF
APPROVED, IN SECOND HALF OF 2024

Source text for Eikon:  ID:nGNX1JLcpH 
Further company coverage:  SPRY.O 

 ((Reuters.Briefs@thomsonreuters.com;))